Breaking News Instant updates and real-time market news.

WMK

Weis Markets

$39.40

-0.06 (-0.15%)

, VLGEA

Village Super Market

$26.80

-0.38 (-1.40%)

13:31
11/11/19
11/11
13:31
11/11/19
13:31

Amazon to open grocery store alternative to Whole Foods, CNET says

CNET's Ben Fox Rubin reported earlier that Amazon (AMZN) confirmed it intends to debut its first new brand of grocery store in Woodland Hills, California in 2020, "as it amps up its ambitious push to become a bigger name in food." According to CNET, Amazon confirmed earlier today that it is is opening a grocery store in Woodland Hills in 2020 with a store format different than Whole Foods. Other companies that may be impacted by this include Casey's General Stores (CASY), Kroger (KR), Supervalu (SVU), Walmart (WMT), Village Super Market (VLGEA) and Weis Markets (WMK). Reference Link

WMK

Weis Markets

$39.40

-0.06 (-0.15%)

VLGEA

Village Super Market

$26.80

-0.38 (-1.40%)

WMT

Walmart

$118.86

-0.55 (-0.46%)

SVU

Supervalu

$0.00

(0.00%)

KR

Kroger

$26.51

-0.5 (-1.85%)

CASY

Casey's General Stores

$166.95

0.07 (0.04%)

AMZN

Amazon.com

$1,770.99

-14.36 (-0.80%)

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

WMK Weis Markets
$39.40

-0.06 (-0.15%)

VLGEA Village Super Market
$26.80

-0.38 (-1.40%)

WMT Walmart
$118.86

-0.55 (-0.46%)

10/23/19
MSCO
10/23/19
NO CHANGE
Target $125
MSCO
Overweight
Procter & Gamble results could bode well for Walmart, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that three of the four companies with the greatest weight in the Consumer Staples Sector SPDR (XLP) - PepsiCo (PEP), Coca-Cola (KO) and now Procter & Gamble (PG) - have reported solid Q3 results. He thinks the group's momentum could have a positive read-through to Walmart (WMT), which will report its fiscal Q3 results on November 14. Gutman added that the correlation between Walmart's total comps and P&G volume growth on a trailing five year basis has improved in the past couple of quarters and both companies' revenue trajectories have trended in a similar direction since "around 2015." Gutman keeps an Overweight rating on Walmart shares with a $125 price target.
11/07/19
NOMU
11/07/19
INITIATION
Target $132
NOMU
Buy
Walmart initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Michael Baker initiated coverage of Walmart with a Buy rating and $132 price target. The analyst cites the company's share gains in stores and online, especially in the grocery sector. Baker adds that Walmart is well positioned to take advantage of a favorable consumer backdrop but can also outperform in a weaker economic environment based on its "defensive" profile.
11/04/19
OPCO
11/04/19
NO CHANGE
Target $125
OPCO
Perform
Walmart price target raised to $125 from $108 at Oppenheimer
Oppenheimer analyst Rupesh Parikh raised his price target for Walmart to $125 from $108 ahead of the Q3 print, saying he has "warmed" towards the company's improving prospects throughout the year, but valuation has kept him sidelined. Parikh, who maintains a Perform rating, says he sees continued market share gains from grocery omni-channel efforts and the ongoing rationalization of the U.S. retail sector, but does not see enough upside to justify an Outperform rating at these levels.
10/30/19
CHLM
10/30/19
NO CHANGE
Target $50
CHLM
Buy
Green Dot's Walmart contract renewal should be major relief, says Craig-Hallum
Craig-Hallum analyst Brad Berning told investors in a research note that GreenDot's (GDOT) MoneyCard 7-year contract renewal with Walmart (WMT) should be a "significant relief" to the stock as he believes the stock has been pricing in that the company would lose the contract. Ahead of the Q3 call, Berning recommends investors aggressively buy Green Dot below $35 in the near-term. The analyst maintains a Buy rating and $50 price target on Green Dot's shares.
SVU Supervalu
$0.00

(0.00%)

11/12/18
LOOP
11/12/18
NO CHANGE
Target $40
LOOP
Buy
United Natural Foods price target lowered to $40 from $45 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on United Natural Foods (UNFI) to $40 after his discussions with its CEO Steve Spinner suggested that the integration of the Supervalu (SVU) acquisition could be "more complex" than anticipated. The analyst still believes in the "strategic rational" for the merger, as the combined entity becomes the "second largest grocery wholesaler in the nation" and the only one that can provide a "full suite of conventional, specialty and natural products". Wolf is keeping his Buy rating on United Natural Foods longer term.
12/04/18
RBCM
12/04/18
NO CHANGE
Target $28
RBCM
Sector Perform
United Natural Foods guidance likely down on Supervalu deal, says RBC Capital
RBC Capital analyst William Kirk kept his Sector Perform rating and $28 price target on United Natural Foods (UNFI) ahead of its Q1 earnings, saying the comparability for the period should be "tricky" given the closing of the Supervalu (SVU) deal and reporting changes of both entities. The analyst warns however that United Natural Foods' guidance may be down based on the latter's operational miss along with the unforeseen related financing costs, estimating its EBITDA outlook at $600M - down from its prior forecast of $655M-$675M. Kirk further believes that the company is " transitioning from a business that can command premium margins to a more conventional margin model," also warning about the "unrelenting risk" coming from Amazon's (AMZN) Whole Foods business.
01/10/19
RBCM
01/10/19
INITIATION
Target $25
RBCM
Outperform
SpartanNash initiated with an Outperform at RBC Capital
RBC Capital analyst Bill Kirk initiated SpartanNash (SPTN) with an Outperform rating and a price target of $25, citing the "volume opportunity" from the integration of United Natural Foods (UNFI) with Supervalu (SVU). The analyst says that the deal should allow SpartanNash market share performance in Food Distribution to improve. Kirk further contends that improvement in food PPI data, which turned positive for the first time in 7 months, is not reflected in the current consensus for SpartanNash, while the headwinds related to freight costs are expected to ease.
KR Kroger
$26.51

-0.5 (-1.85%)

11/08/19
UBSW
11/08/19
INITIATION
Target $85
UBSW
Neutral
Beyond Meat initiated with a Neutral at UBS
UBS analyst Steven Strycula initiated coverage of Beyond Meat (BYND) with a Neutral rating and $85 price target. The analyst is positive on the company's first-mover advantage in "plant-based meat" industry that offers "favorable" growth trends of low penetration and high total addressable market. Strycula notes however that the valuation on the stock looks full and new competitive threats may emerge from "Impossible, Kroger (KR), etc."
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $26
JEFF
Hold
Jefferies 'checking out' of Kroger after 15% rally in three months
Jefferies analyst Christopher Mandeville downgraded Kroger to Hold from Buy with a price target of $26, down from $29. Following the stock's 15% rally in three months, the analyst is "checking out" as his confidence in Kroger's long-term grocery strategy and management's ability to effectively communicate "wanes." The company's customer fulfillment center strategy is a "costly, time consuming venture" with high risk in a nascent market, Mandeville tells investors in a research note. The analyst also sees no drivers for notable comp progress in fiscal 2020.
10/10/19
10/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kroger (KR) downgraded to Hold from Buy at Jefferies with analyst Christopher Mandeville saying after the stock's 15% rally in three months, the analyst is "checking out" as his confidence in Kroger's long-term grocery strategy and management's ability to effectively communicate "wanes." 2. HP Inc. (HPQ) downgraded to Sell from Neutral at Goldman Sachs while Cisco (CSCO) was downgraded to Neutral from Buy. 3. Continental Resources (CLR) downgraded to Neutral from Buy at Mizuho analyst Paul Sankey saying while the company has taken steps to reduce leverage and initiated its own cash return strategy, he has too much concern about the trajectory of spending and the quality of its unconventional opportunity longer-term to remain Buy-rated. 4. Evergy (EVRG) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith citing the Missouri PSC vote in favor of petitioners against the company in the ongoing Sibley Generating Station complaint. 5. ForeScout (FSCT) downgraded to Neutral from Overweight at JPMorgan with analyst Sterling Auty citing the company's announcement of preliminary September quarter revenue that was about 10% short of expectations due primarily to macroeconomic conditions in EMEA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/19
JPMS
10/24/19
NO CHANGE
Target $27
JPMS
Neutral
Kroger price target raised to $27 from $24 at JPMorgan
JPMorgan analyst Ken Goldman raised his price target for Neutral-rated Kroger to $27 from $24 ahead of the company's investor conference on November 5.
CASY Casey's General Stores
$166.95

0.07 (0.04%)

09/10/19
JEFF
09/10/19
NO CHANGE
Target $192
JEFF
Buy
Jefferies a buyer of Casey's ahead of this morning's earnings call
Jefferies analyst Christopher Mandeville recommends buying shares of Casey's General Stores on weakness ahead of this morning's earnings conference call. Despite a $6.6M inventory adjustment, earnings and EBITDA "beat soundly" as Casey's provided "impressive" expense control and "outsized" fuel margins, Mandeville tells investors in a research note. Further, potentially positive quarter-to-date color on the call and confirmation of an imminent loyalty launch "should only help" the stock, adds the analyst. He keeps a Buy rating on Casey's General Stores with a $192 price target.
09/11/19
BMOC
09/11/19
NO CHANGE
Target $170
BMOC
Market Perform
Casey's General Stores price target raised to $170 from $140 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Casey's General Stores to $170 after its Q1 results, saying the company's fuel price optimization has been driving its earnings since the beginning of its "value creation plan". The analyst notes that she sees continued runway in that trend, even though she warns that an acceleration in the in-store trends may be "difficult" to achieve, keeping her Market Perform rating on the stock. Bania still raises her FY20 and FY21 EPS views on Casey's General Stores by 77c and $1.15 to $6.41 and $6.80 respectively to reflect its higher fuel margins.
09/11/19
WELS
09/11/19
NO CHANGE
Target $165
WELS
Market Perform
Casey's General Stores price target raised to $165 form $145 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Casey's General Stores to $165 from $145 after the company delivered a "solid" Q1 led by "strong" fuel margins, "solid" Grocery comps and continued cost discipline. The analyst believes new CEO Darren Rebelez's decision to focus on the near-term deliverables of the company's Value Creation Plan is wise, although he notably did not commit to any long-term targets. Herzog reiterates a Market Perform rating on the shares.
09/11/19
SPHN
09/11/19
NO CHANGE
Target $197
SPHN
Overweight
Casey's General Stores price target raised to $197 from $181 at Stephens
Stephens analyst Ben Bienvenu said Casey's General Stores' in-store comps and margins remained "solid" in Q1. He also expects management comments that procurement savings and pricing initiatives, expected to be significant contributors this year, had a minimal impact during the quarter to be "very encouraging to bulls." The analyst, who sees Casey's being in the middle innings of a multi-year value creation plan, keeps an Overweight rating on the stock and raised his price target on the shares to $197 from $181.
AMZN Amazon.com
$1,770.99

-14.36 (-0.80%)

10/28/19
WBLR
10/28/19
NO CHANGE
WBLR
Outperform
Amazon likely to challenge Microsoft DoD contract win, says William Blair
Microsoft's (MSFT) JEDI contact with the Department of Defense could be worth $10B over a 10-year period if the Pentagon exercises all options under the contract, William Blair analyst Jason Ader tells investors in a research note. He points out that the selection of Microsoft was a "major surprise," as most press reports over the past year pegged Amazon Web Services as the clear favorite. The analyst suspects AWS will challenge the government's decision in court, claiming bias, especially given President Trump's negative public statements against Amazon CEO Jeff Bezos. However, he believes the JEDI win "epitomizes the significant strides that Microsoft's cloud franchise has made under the tenure of CEO Satya Nadella." He expects JEDI could further narrow the market share gap between Azure and AWS and keeps an Outperform rating on Microsoft shares.
11/05/19
RSBL
11/05/19
UPGRADE
Target $13
RSBL
Buy
Applied Optoelectronics upgraded to Buy ahead of guidance at Rosenblatt
As previously reported, Rosenblatt analyst Jun Zhang upgraded Applied Optoelectronics (AAOI) to Buy from Neutral with a price target of $13, up from $10. When the company reports Q3 results tomorrow, Zhang believes it will provide guidance for sequential revenue growth in Q4, powered by Microsoft's (MSFT) increasing demand for 100G products and demand from Amazon (AMZN) for 40G products. In addition to demand in the U.S. hyperscale market, Zhang sees Applied benefiting in 2020 from potential opportunities in 5G, a likely design wins at ZTE (ZTCOY), and potential opportunities to supply to Cisco (CSCO) clients.
11/06/19
DADA
11/06/19
NO CHANGE
Target $20
DADA
Buy
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
DA Davidson analyst Tom Forte reiterates a Buy rating on Sonos (SONO) with a $20 price target following Alphabet's (GOOG, GOOGL) acquisition of Fitbit (FIT). The stock in early trading is up 82c to $14.28. The analyst sees Sonos as the most likely company he covers to have its shares rally from either an improvement in investor perception or a takeover. Sonos is the "best house" on the "bad block" of hardware companies, and is "adjacent to the mansion on the neighboring block, Apple (AAPL)," Forte tells investors in a research note. Similar to Apple, Sonos makes products that are superior to the competition, has an eye for design, and boasts a premium brand that enables it to sell its products at higher prices than others, the analyst says. Further, Forte believes that similar to Fitbit not getting proper credit for its healthcare-related efforts, Sonos does not get credit for its superior technology and premium brand. As such, he sees Sonos as a "natural acquisition target for Apple." Furthermore, while less obvious than Apple, Amazon (AMZN) could acquire Sonos to advance its connected home efforts, according to Forte. The analyst also thinks the company could go private given the "lack of appreciation by Wall Street."
10/28/19
COMP
10/28/19
NO CHANGE
COMP
Compass Point says Amazon could challenge Microsoft winning JEDI contract
Compass Point policy analyst Isaac Boltansky said, following the Department of Defense awarding the $10B JEDI contract to Microsoft (MSFT) over Amazon (AMZN), that his channel checks indicated Amazon could challenge the decision. However, he believes that while there will be "a degree of handwringing" about the political issues surrounding the contract, he feels "lawmakers are unlikely to wade too deeply into these waters given the increasing toxicity of the Big Tech conversation in Washington." Boltansky added that the JEDI contract win was a "significant victory for Microsoft," and that it could also yield some benefit for Oracle (ORCL), as it has a cloud interoperability arrangement with Microsoft.

TODAY'S FREE FLY STORIES

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary  »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change  »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change  »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change  »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change  »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary  »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change  »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change  »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary at Piper Jaffray »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.